Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Gold

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trialSeza A Gulec, Steven J Cohen, Kenneth L Pennington, et al.
Human Reproduction (Oxford, England)|February 13, 2018
The clinical utility of PGD with HLA matching: a collaborative multi-centre ESHRE studyG Kakourou, S Kahraman, G C Ekmekci, et al.
Cancer|May 10, 2012
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trialAllyson J Ocean, Kenneth L Pennington, Michael J Guarino, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trialSeza A Gulec, Steven J Cohen, Kenneth L Pennington, et al.
Human Reproduction (Oxford, England)|February 13, 2018
The clinical utility of PGD with HLA matching: a collaborative multi-centre ESHRE studyG Kakourou, S Kahraman, G C Ekmekci, et al.
Cancer|May 10, 2012
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trialAllyson J Ocean, Kenneth L Pennington, Michael J Guarino, et al.
Pageof 8